Abstract: G protein-coupled receptors (GPCRs) represent a large fraction of current pharmaceutical targets, and of the GPCRs, the 2 adrenergic receptor ( 2 AR) is one of the most extensively studied. Previously, the X-ray crystal structure of 2 AR has been determined in complex with two partial inverse agonists, but the global impact of additional ligands on the structure or local impacts on the binding site are not well-understood. To assess the extent of such ligand-induced conformational differences, we determined the crystal structures of a previously described engineered 2 AR construct in complex with two inverse agonists: ICI 118,551 (2.8 Å), a recently described compound (2.8 Å) (Kolb et al, 2009) , and the antagonist alprenolol (3.1 Å). The structures show the same overall fold observed for the previous 2 AR structures and demonstrate that the ligand binding site can accommodate compounds of different chemical and pharmacological properties with only minor local structural rearrangements. All three compounds contain a hydroxy-amine motif that establishes a conserved hydrogen bond network with the receptor and chemically diverse aromatic moieties that form distinct interactions with 2 AR. Furthermore, receptor ligand cross-docking experiments revealed that a single 2 AR complex can be suitable for docking of a range of antagonists and inverse agonists but also indicate that additional ligand-receptor structures may be useful to further improve performance for in-silico docking or lead-optimization in drug design.
G protein-coupled receptors (GPCRs) are the largest protein family involved in signal transduction across membranes. 1 The 2 adrenergic receptor ( 2 AR) is one of the best characterized members of the GPCR family, for which pharmacologically distinct highaffinity ligands have been described as (i) agonists (compounds activating signaling), (ii) antagonists (blocking agonist signaling), or (iii) inverse agonists (blocking both agonist and basal signaling). The human 2 AR structure has previously been determined in complex with two partial inverse agonists, carazolol ( Car 2 AR-t4l) 2 and timolol ( Tim 2 AR-t4l) 3 and turkey 1 adrenergic receptor has been determined in complex with the antagonist cyanopindolol. 4 A number of studies have used these structures for in silico ligand docking and discovery of new scaffolds of 2 AR ligands. [5] [6] [7] [8] Currently, a challenge for rational drug design and docking studies is to ascertain to what degree the conformation of the ligand binding site changes upon interaction with different compounds. To assess the extent of such ligand-induced conformational differences and reveal further details of ligand binding, we determined the X-ray crystal structure of 2 AR in complex with two of the most potent inverse agonists and the well-known antagonist alprenolol.
Using a previously described engineered 2 AR construct, 3 the cocrystal structures of 2 AR-t4l in complex with 1 ( Figure 2 ). Ligand mass spectrometry identification, receptor thermostability analysis, and the crystal structures reported here are consistent with the presence of compound 1, 2, and 3 bound in each of the 2 AR-t4l complexes. The electron density shows the compounds bound to the same orthosteric binding site as carazolol and timolol, with minor differences in side chain orientations that reflect specific ligandreceptor interactions (Figure 2) .
The binding pocket of 2 AR can be described as a narrow cleft surrounded by mostly hydrophobic residues, with few polar residues located at the 'front' (Asp113 3.32 , Tyr316
7.43 and Asn312 7.39 ) and 'back' (Ser203 5.42 , S207
5.46 and Asn293 6.55 ) of the binding site (Figures 1 and 2 ). Compounds 2, 3, carazolol, and timolol contain an aliphatic oxypropanolamine moiety (compound 1 has a structurally similar oxybutanolamine), referred to as the ligand tail, and chemically and structurally diverse aromatic systems defined as the ligand head groups.
The amine and hydroxyl groups in the tails of 1, 2, and 3 establish a conserved hydrogen bond network with the receptor polar triad Asp113 3.32 , Tyr316 7.43 , and Asn312 7.39 in the 'front' of the pocket that closely resembles the ligand interactions observed in the Compared to carazolol, timolol, and compound 2, the dihydroindene head group of the inverse agonist compound 1 9 is smaller and does not contain any polar groups that could accept or donate hydrogen bonds. Also, the ICI 2 AR-t4l structure shows the additional methyl group in the tail of compound 1 in the vicinity of Phe193 5.32 and the cyclopentene ring of the dihydro-indene in close proximity to the Phe289 6.51 and Phe193 5.32 side chains in the 'back' of the binding site (Figures 1 and 2 ). Furthermore, 1 has an additional methyl group on the aromatic system, and a comparison between all 2 AR-t4l-ligand structures shows that this compound requires some rearrangements in The geometry adopted by compound 2 in the active site of the 2 2 AR-t4l structure overlaps well with that of carazolol in the Car 2 AR-t4l structure, and we also observe a hydrogen bond between the side chain of Ser203 5.42 (TM V) and the benzofuran oxygen of compound 2 (Figures 1 and 2 ). In addition, the ethyl-carboxylate moiety extends toward Asn293 6.55 and allows for an additional hydrogen bond interaction between the ethoxy oxygen and the amine group of Asn293 6.55 side chain in TM VI (Figure 2) . A comparison between the available crystal structures of 2 AR-ligand complexes reveals that compound 2 is the only ligand that connects TM V and VI through hydrogen bond networks. Other than a few minor differences, the compound 2 pose in the 2 2 AR-t4l structure is similar to that predicted by Kolb et al. 6 with an rmsd of ∼0.9 Å. Unlike compound 1, 2, timolol, and carazolol, which contain at least one cyclic system other than the aromatic ring, the allylbenzene head group of the antagonist compound 3 10 is smaller and contains only a short prop-1-ene attached to the benzene group. Although the Alp 2 AR-t4l structure has been determined at 3.1 Å resolution and therefore decreased confidence in the ligand placement (see Supporting Information), there is sufficient electron density detail to orient the prop-1-ene chain of 3 in the same location as the cyclic system present on the other four compounds (Figure 2) .
Although we observe a conserved binding mode for the -hydroxy-amine motif on the ligand tails, a common feature among the 'classical' scaffold of 2 AR ligands with inverse agonist, antagonist, or full/partial agonist activities, 5 all 2 AR-t4l-ligand crystal structures show distinct interactions between the head groups of the ligands and the receptor (Figures 1 and 2) . While the aromatic moieties of all compounds are anchored by strong hydrophobic interactions in the binding cleft, specific hydrogen bonds are also established by substituent moieties in compound 2, timolol, and carazolol. Recently performed large scale docking and virtual screening studies 6, 11 suggest that the Car 2 AR-t4l structure is highly efficient in screening for a wide range of antagonists and inverse agonists, though certain changes in the binding pocket may still be required for optimal binding of high affinity agonists. Since almost identical conformations were found for the ligand binding site in all five 2 AR-t4l structures, we set out to investigate whether a single complex structure could be suitable for docking a range of antagonists and inverse agonists. 6, 11 To test this hypothesis, we performed cross-docking experiments where each of the five ligands was docked into each 2 AR-t4l structure. The results (see Supporting Information) show excellent accuracy of docking pose predictions (rmsd < 1 Å) and high binding scores (ICM Score < -30 kJ/mol) for the docked compounds. The exception is compound 1, which cross-docks poorly into all other crystal structures, mostly because of its exocyclic methyl group, which cannot be optimally accommodated within the slightly smaller pockets of the other structures. Overall, these results support the applicability of different 2 AR-ligand structures for docking and virtual screening of antagonists and inverse agonists. Substantially better binding scores for self-docking (except for compound 2), however, suggest that additional ligand-receptor structures can further improve the performance of in silico docking and can be particularly valuable for rational drug design at lead optimization stages.
Minimal structural differences between the three complexes reported here indicate that the ligands studied exert only a minor local impact on the structure of the receptor. The most conserved region is the 'front' part of the orthosteric binding pocket of the receptor, and therefore it is unlikely to be associated with distinct pharmacological properties of antagonists and inverse agonists. Instead, differences in specific interactions between the ligand and receptor TMs III, V, and VI that take place through the aromatic ring system appear to define the pharmacologic effects. Note that agonists, characterized by a distinctly shorter "tail" and multiple polar substituents in the aromatic system, are likely to introduce other changes in the 2 AR binding pocket associated with activation of the receptor, although the degree of these changes are yet to be structurally observed.
The result that 2 AR bound to pharmacologically distinct ligands (antagonists and inverse agonists) have virtually identical backbone conformations in the crystal structures suggests that the conformational changes capable of modifying signaling properties are very small, beyond the resolution of the obtained data. Alternatively, the major effect of inverse agonists, antagonists, and extrapolated to agonists on 2 AR is not on modifying a specific conformation with large conformational changes, but on minor structural changes and a significantly larger contribution from receptor dynamics. The answer to this intriguing problem should likely arrive from a combination of crystallography with techniques sensitive to dynamics, such as NMR, 12 EPR, 13 and HDX. 14 
